CoChat

Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles

Open access

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Abstract

. These results suggest that PD-L1 on EVs may be another mechanism for glioblastoma to suppress antitumor immunity and support the potential of EVs as biomarkers in tumor patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1126/sciadv.aar2766

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Glioblastoma EVs inhibit T cell activation in an antigen-specific manner. (A) EVs from human GSC cultures inhibit both CD4+ and CD8+ T cell activation and proliferation. PBMCs (isolated from eight human volunteers, n = 8) were treated with anti-CD3 (500 ng/ml) to activate TCR signaling in the presence or absence of GSC EVs (5 μg/ml; isolated from four different GSCs, that is, n = 4) for 2 days. Top: Dot plots of CD69 and CD25 and proliferation flow cytometry data. Bottom: Percent changes of CD69 (left) and CD25 (middle) compared to anti-CD3 alone and percent change of proliferating cells (right) compared to anti-CD3 treatment alone after 3 days for CD4+ and CD8+ T cells, measured by carboxyfluorescein diacetate succinimidyl ester (CFSE) content. (B) EVs from CT2A glioma cells inhibited CD8+ T cells in an antigen-specific manner. Percent CD69 expression change (left) of CD8+ T cells isolated from transgenic P14 mice reacting against gp33 peptide presented by DC ± CT2A EVs; proliferation change (right) of gp33 antigen–specific P14 CD8+ T cells ± CT2A EVs measured by CFSE (n = 4). Statistical analysis was performed by two-tailed Student’s t test (****P < 0.0001). Bars represent means ± SD of each of the eight T cell preparations after incubation with one EV preparation from each of the four gender-matched GSC EVs.
Fig. 1 Glioblastoma EVs inhibit T cell activation in an antigen-specific manner. (A) EVs from human GSC cultures inhibit both CD4+ and CD8+ T cell activation and proliferation. PBMCs (isolated from eight human volunteers, n = 8) were treated with anti-CD3 (500 ng/ml) to activate TCR signaling in the presence or absence of GSC EVs (5 μg/ml; isolated from four different GSCs, that is, n = 4) for 2 days. Top: Dot plots of CD69 and CD25 and proliferation flow cytometry data. Bottom: Percent changes of CD69 (left) and CD25 (middle) compared to anti-CD3 alone and percent change of proliferating cells (right) compared to anti-CD3 treatment alone after 3 days for CD4+ and CD8+ T cells, measured by carboxyfluorescein diacetate succinimidyl ester (CFSE) content. (B) EVs from CT2A glioma cells inhibited CD8+ T cells in an antigen-specific manner. Percent CD69 expression change (left) of CD8+ T cells isolated from transgenic P14 mice reacting against gp33 peptide presented by DC ± CT2A EVs; proliferation change (right) of gp33 antigen–specific P14 CD8+ T cells ± CT2A EVs measured by CFSE (n = 4). Statistical analysis was performed by two-tailed Student’s t test (****P < 0.0001). Bars represent means ± SD of each of the eight T cell preparations after incubation with one EV preparation from each of the four gender-matched GSC EVs.CC BY-NC · PubMed Central
Fig. 2 Glioblastoma EVs contain PD-L1 and block TCR-mediated T cell activation. (A) Detection of PD-L1 by Western blot in glioblastoma EVs. Four GSCs were analyzed for their cellular and EV PD-L1 expression (red, PD-L1high; blue, PD-L1low). GAPDH, glyceraldehyde-3-phosphate dehydrogenase. (B) PD-L1 is found in primary cell cultures (PCCs) from glioblastoma patients and EVs isolated from these cell cultures. (C and D) PD-L1high and PD-L1low GSC EVs inhibit CD4+ (C) and CD8+ (D) T cell activation. Percent CD69 and CD25 and CD69+CD25+ expression change compared to anti-CD3 for 2 days ± glioblastoma EVs (5 μg/ml) from four different GSCs. Anti-CD3–stimulated PBMCs were from eight human volunteers ± PD-L1high/low EVs, and NSC EVs were added to anti-CD3–stimulated PBMCs from three human volunteers. (E) GSC EVs can inhibit T cell proliferation. Percent change of proliferating cells compared to anti-CD3 treatment after 3 days for CD4+ and CD8+ T cells, measured by CFSE content (aCD3 ± PD-L1high/low EVs, n = 7; NSC EVs, n = 3). (F) T cell inhibition is partially mediated by a direct effect on T cells. Left: unsorted PBMCs. Right: CD3+ cells are enriched after sorting. (G) CD3+CD4+ (left) and CD3+CD8+ (right) cells (n = 3) after treatment. Statistical analysis was performed by one-way analysis of variance (ANOVA), with post hoc Bonferroni’s correction (****P < 0.0001, ***P < 0.001, **P < 0.01, and *P < 0.05; ns, not significant.). Examples of the flow cytometry data are available at http://harveycushing.bwh.harvard.edu/chiocca-lab/.
Fig. 2 Glioblastoma EVs contain PD-L1 and block TCR-mediated T cell activation. (A) Detection of PD-L1 by Western blot in glioblastoma EVs. Four GSCs were analyzed for their cellular and EV PD-L1 expression (red, PD-L1high; blue, PD-L1low). GAPDH, glyceraldehyde-3-phosphate dehydrogenase. (B) PD-L1 is found in primary cell cultures (PCCs) from glioblastoma patients and EVs isolated from these cell cultures. (C and D) PD-L1high and PD-L1low GSC EVs inhibit CD4+ (C) and CD8+ (D) T cell activation. Percent CD69 and CD25 and CD69+CD25+ expression change compared to anti-CD3 for 2 days ± glioblastoma EVs (5 μg/ml) from four different GSCs. Anti-CD3–stimulated PBMCs were from eight human volunteers ± PD-L1high/low EVs, and NSC EVs were added to anti-CD3–stimulated PBMCs from three human volunteers. (E) GSC EVs can inhibit T cell proliferation. Percent change of proliferating cells compared to anti-CD3 treatment after 3 days for CD4+ and CD8+ T cells, measured by CFSE content (aCD3 ± PD-L1high/low EVs, n = 7; NSC EVs, n = 3). (F) T cell inhibition is partially mediated by a direct effect on T cells. Left: unsorted PBMCs. Right: CD3+ cells are enriched after sorting. (G) CD3+CD4+ (left) and CD3+CD8+ (right) cells (n = 3) after treatment. Statistical analysis was performed by one-way analysis of variance (ANOVA), with post hoc Bonferroni’s correction (****P < 0.0001, ***P < 0.001, **P < 0.01, and *P < 0.05; ns, not significant.). Examples of the flow cytometry data are available at http://harveycushing.bwh.harvard.edu/chiocca-lab/.CC BY-NC · PubMed Central
Fig. 3 Glioblastoma EVs contain PD-L1 that directly interacts with PD1, and the interaction is displaced by anti-PD1 treatment. (A and B) PD1 blockade prevents the inhibition of PD-L1high GSC EVs on PBMCs. Percent change in CD69 expression for CD4+ (A) and CD8+ (B) T cells. PD1 blocking antibody (10 μg/ml) or isotype control (10 μg/ml) was added at day 0 (n = 7 PBMC donors, means ± SD). (C and D) PD1 blockade furthermore prevents the inhibition of PD-L1high GSC EVs on CD3+ isolated cells. CD3+CD4+ (C) and CD3+CD8+ (D) cells (n = 3) after treatment. (E) PD-L1–carrying, palmtdT-labeled PD-L1high GSC EVs can bind to wells coated with recombinant PD1, whereas PD1 antibody blockade inhibits EV binding. Representative confocal images are shown on the left, whereas quantification is provided on the right. Spots per field of view (FOV) on the y axis represent palmtdT-positive dots. Scale bar, 50 μm; ×500 magnification inserts; quadruplicates as means ± SD. One-way ANOVA, with post hoc Bonferroni’s correction, was used to differentiate multiple groups (****P < 0.0001, ***P < 0.001, **P < 0.01, and *P < 0.05).
Fig. 3 Glioblastoma EVs contain PD-L1 that directly interacts with PD1, and the interaction is displaced by anti-PD1 treatment. (A and B) PD1 blockade prevents the inhibition of PD-L1high GSC EVs on PBMCs. Percent change in CD69 expression for CD4+ (A) and CD8+ (B) T cells. PD1 blocking antibody (10 μg/ml) or isotype control (10 μg/ml) was added at day 0 (n = 7 PBMC donors, means ± SD). (C and D) PD1 blockade furthermore prevents the inhibition of PD-L1high GSC EVs on CD3+ isolated cells. CD3+CD4+ (C) and CD3+CD8+ (D) cells (n = 3) after treatment. (E) PD-L1–carrying, palmtdT-labeled PD-L1high GSC EVs can bind to wells coated with recombinant PD1, whereas PD1 antibody blockade inhibits EV binding. Representative confocal images are shown on the left, whereas quantification is provided on the right. Spots per field of view (FOV) on the y axis represent palmtdT-positive dots. Scale bar, 50 μm; ×500 magnification inserts; quadruplicates as means ± SD. One-way ANOVA, with post hoc Bonferroni’s correction, was used to differentiate multiple groups (****P < 0.0001, ***P < 0.001, **P < 0.01, and *P < 0.05).CC BY-NC · PubMed Central
Fig. 4 PD-L1 is up-regulated in response to IFN-γ in PD-L1low GSCs and their EVs that can now suppress activated T cells in a PD-L1–dependent manner. (A) Glioma GSCs up-regulate PD-L1 in vitro in response to activated PBMC supernatants. PBMCs were stimulated with anti-CD3, and supernatants were collected and co-incubated with GSCs (G44, a PD-L1low GSC) in the presence or absence of anti–IFN-γ. PD-L1 expression was measured by flow cytometry. DMEM, Dulbecco’s modified Eagle’s medium. (B) IFN-γ–mediated increase of PD-L1 expression levels in PD-L1High and PD-L1low GSCs as shown by Western blots of four different GSCs. (C and D) EVs derived from IFN-γ–treated PD-L1low GSCs inhibit anti-CD3–stimulated T cell activation, and this can be partially reversed by PD1 blockade. Inhibition potential was measured by the percentage change of CD69+ levels on anti-CD3–stimulated CD3+CD4+ (C) or CD3+CD8+ (D) cells, isolated from five human volunteers (means ± SD). Representative dot plots for (C) and (D) can be found in fig. S4C. (E) PD-L1low EVs up-regulated indoleamine 2,3-dioxygenase (IDO) mRNA in PBMCs treated with PD-L1low EVs. Quantitative polymerase chain reaction (qPCR) expression levels are shown (n = 3). (F) PD-L1low EVs cause interleukin-10 (IL-10) up-regulation in PBMCs. IL-10 cytokine (left) and qPCR expression levels (right) are shown (n = 3). (G and H) Immunosuppressive molecules IDO and IL-10 primarily derive from the CD3-negative population. IDO (G) and IL-10 (H) mRNA levels are shown after CD3+ magnetic-activated cell sorting (n = 3). Data sets consist of EVs from four different glioblastoma cell lines with means ± SD. One-way ANOVA, with post hoc Bonferroni’s correction, was used to differentiate multiple groups (****P < 0.0001, ***P < 0.001, **P < 0.01, and *P < 0.05). Student’s t test was used to differentiate between two groups, and one-way ANOVA with post hoc Bonferroni’s correction was used for multiple groups (****P < 0.0001, ***P < 0.001, **P < 0.01, and *P < 0.05).
Fig. 4 PD-L1 is up-regulated in response to IFN-γ in PD-L1low GSCs and their EVs that can now suppress activated T cells in a PD-L1–dependent manner. (A) Glioma GSCs up-regulate PD-L1 in vitro in response to activated PBMC supernatants. PBMCs were stimulated with anti-CD3, and supernatants were collected and co-incubated with GSCs (G44, a PD-L1low GSC) in the presence or absence of anti–IFN-γ. PD-L1 expression was measured by flow cytometry. DMEM, Dulbecco’s modified Eagle’s medium. (B) IFN-γ–mediated increase of PD-L1 expression levels in PD-L1High and PD-L1low GSCs as shown by Western blots of four different GSCs. (C and D) EVs derived from IFN-γ–treated PD-L1low GSCs inhibit anti-CD3–stimulated T cell activation, and this can be partially reversed by PD1 blockade. Inhibition potential was measured by the percentage change of CD69+ levels on anti-CD3–stimulated CD3+CD4+ (C) or CD3+CD8+ (D) cells, isolated from five human volunteers (means ± SD). Representative dot plots for (C) and (D) can be found in fig. S4C. (E) PD-L1low EVs up-regulated indoleamine 2,3-dioxygenase (IDO) mRNA in PBMCs treated with PD-L1low EVs. Quantitative polymerase chain reaction (qPCR) expression levels are shown (n = 3). (F) PD-L1low EVs cause interleukin-10 (IL-10) up-regulation in PBMCs. IL-10 cytokine (left) and qPCR expression levels (right) are shown (n = 3). (G and H) Immunosuppressive molecules IDO and IL-10 primarily derive from the CD3-negative population. IDO (G) and IL-10 (H) mRNA levels are shown after CD3+ magnetic-activated cell sorting (n = 3). Data sets consist of EVs from four different glioblastoma cell lines with means ± SD. One-way ANOVA, with post hoc Bonferroni’s correction, was used to differentiate multiple groups (****P < 0.0001, ***P < 0.001, **P < 0.01, and *P < 0.05). Student’s t test was used to differentiate between two groups, and one-way ANOVA with post hoc Bonferroni’s correction was used for multiple groups (****P < 0.0001, ***P < 0.001, **P < 0.01, and *P < 0.05).CC BY-NC · PubMed Central
Fig. 5 PD-L1 expression correlates with M glioblastoma and IFN-γ response genes. (A) Analysis of TCGA RNA-seq data for PD-L1 expression shows mesenchymal enrichment. The dots represent individual patients. (B) PD-L1 expression correlates with IFN-γ response factor (IRF1), human leukocyte antigen A (HLA-A), and intercellular adhesion molecule 1 (ICAM1) levels. (C) Ivy Glioma database RNA-seq analysis of laser-captured specimens from different regions of glioblastomas (leading edge, infiltrating tumor, cellular tumor, and perinecrotic areas) shows anatomical clustering of PD-L1 with known IFN-γ response genes. (D) The expression of PD-L1 correlates with immune response genes in perinecrotic and pseudopalisading niches of glioblastoma tumors. The correlation of PD-L1 expression (R > 0.6) with Ivy GAP database–based expression signatures in different anatomic areas of glioblastoma was analyzed (LE, leading edge; IT, infiltrating tumor; CT, cellular tumor; PZ, perinecrotic zone; PC, pseudopalisading cells around necrosis; HBV, hyperplastic blood vessels; MP, microvascular proliferation; P, proneural; C, classical; M, mesenchymal; N, neural). (E) The expression of PD-L1 inversely correlates with T cell markers in the tumor anatomic niche. Selected genes were queried with Ivy GAP database–based expression signatures in different anatomic areas of glioblastomas. The box denotes PZ and PC areas of tumor. (F) The expression of PD-L1 positively correlates with mesenchymal tumor markers in the tumor anatomic niche. Selected genes were queried with Ivy GAP database–based expression signatures in different anatomic areas of glioblastoma. The boxes denote PZ and PC areas of tumor. The Kruskal-Wallis test with Dunn’s correction was used to differentiate TCGA groups (****P < 0.0001, **P < 0.01, and *P < 0.05).
Fig. 5 PD-L1 expression correlates with M glioblastoma and IFN-γ response genes. (A) Analysis of TCGA RNA-seq data for PD-L1 expression shows mesenchymal enrichment. The dots represent individual patients. (B) PD-L1 expression correlates with IFN-γ response factor (IRF1), human leukocyte antigen A (HLA-A), and intercellular adhesion molecule 1 (ICAM1) levels. (C) Ivy Glioma database RNA-seq analysis of laser-captured specimens from different regions of glioblastomas (leading edge, infiltrating tumor, cellular tumor, and perinecrotic areas) shows anatomical clustering of PD-L1 with known IFN-γ response genes. (D) The expression of PD-L1 correlates with immune response genes in perinecrotic and pseudopalisading niches of glioblastoma tumors. The correlation of PD-L1 expression (R > 0.6) with Ivy GAP database–based expression signatures in different anatomic areas of glioblastoma was analyzed (LE, leading edge; IT, infiltrating tumor; CT, cellular tumor; PZ, perinecrotic zone; PC, pseudopalisading cells around necrosis; HBV, hyperplastic blood vessels; MP, microvascular proliferation; P, proneural; C, classical; M, mesenchymal; N, neural). (E) The expression of PD-L1 inversely correlates with T cell markers in the tumor anatomic niche. Selected genes were queried with Ivy GAP database–based expression signatures in different anatomic areas of glioblastomas. The box denotes PZ and PC areas of tumor. (F) The expression of PD-L1 positively correlates with mesenchymal tumor markers in the tumor anatomic niche. Selected genes were queried with Ivy GAP database–based expression signatures in different anatomic areas of glioblastoma. The boxes denote PZ and PC areas of tumor. The Kruskal-Wallis test with Dunn’s correction was used to differentiate TCGA groups (****P < 0.0001, **P < 0.01, and *P < 0.05).CC BY-NC · PubMed Central
Fig. 6 Glioblastoma patient–derived serum and plasma EVs contain PD-L1 DNA whose levels correlate with tumor volume. (A) PD-L1 DNA enrichment is found specifically in patient-derived EVs (healthy controls, n = 5; glioblastoma patients, n = 21). (B) PD-L1 DNA enrichment highly correlates with CET of <60 cm3 (Pearson’s correlation with nonlinear regression, r = 0.637, R2 = 0.406, P = 0.0025). (C) PD-L1 expression in tumors correlates with PD-L1 DNA in patient blood (Pearson’s correlation with nonlinear regression, r = 0.733, R2 = 0.538, P = 0.0102).
Fig. 6 Glioblastoma patient–derived serum and plasma EVs contain PD-L1 DNA whose levels correlate with tumor volume. (A) PD-L1 DNA enrichment is found specifically in patient-derived EVs (healthy controls, n = 5; glioblastoma patients, n = 21). (B) PD-L1 DNA enrichment highly correlates with CET of <60 cm3 (Pearson’s correlation with nonlinear regression, r = 0.637, R2 = 0.406, P = 0.0025). (C) PD-L1 expression in tumors correlates with PD-L1 DNA in patient blood (Pearson’s correlation with nonlinear regression, r = 0.733, R2 = 0.538, P = 0.0102).CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 42 references

Cited by

Items 101–200 of 632

Metadata

Authors
Ricklefs, F. L., Alayo, Q., Krenzlin, H., Mahmoud, A. B., Speranza, M. C., Nakashima, H., Hayes, J. L., Lee, K., Balaj, L., Passaro, C., Rooj, A. K., Krasemann, S., Carter, B. S., Chen, C. C., Steed, T., Treiber, J., Rodig, S., Yang, K., Nakano, I., Lee, H., Weissleder, R., Breakefield, X. O., Godlewski, J., Westphal, M., Lamszus, K., Freeman, G. J., Bronisz, A., Lawler, S. E., & Chiocca, E. A.
Affiliations
  • Brigham and Women's Hospital (US)
  • University of California, Berkeley (US)
  • Massachusetts General Hospital (US)
  • University Medical Center Hamburg-Eppendorf (DE)
  • University of California San Diego (US)
  • Comprehensive Cancer Center, University of Birmingham, Birmingham, AL 35294, USA.
  • Harvard University (US)
Corresponding author
  • Lawler, Sean E.
  • Chiocca, E. Antonio
Venue
Science Advances
Published
2018-03-02
Volume
4
Issue
3
Pages
eaar2766-eaar2766
ISSN
2375-2548 (ISSN-L)
OpenAlex
W2793992337
Cited by
610
References
42
Citations by year
2026: 48 · 2025: 68 · 2024: 76 · 2023: 76 · 2022: 85 · 2021: 111 · 2020: 75 · 2019: 56 · 2018: 15
FWCI
22.86
Type
journal article
Language
en
Open access
Locations
  • Science Advances (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
Funders
  • National Institutes of Health (CA176203-01A1)
  • National Cancer Institute (P01 CA69246)
  • Deutsche Forschungsgemeinschaft (RI 2616/1-1, RI 2616/2-1)
  • National Institute of Health (NCI P01 CA69246)
  • American-Italian Cancer Foundation Post-doctoral Research Fellowship
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
Keywords
glioblastoma, PD-L1, extracellular vesicles, immune evasion, antitumor immunity, tumor microenvironment, biomarkers
MeSH terms
Extracellular Vesicles, Antigens, Neoplasm, Brain Neoplasms, Glioblastoma, Humans, Interferon-gamma, Lymphocyte Activation, Receptors, Antigen, T-Cell, T-Lymphocytes, Neoplastic Stem Cells, Up-Regulation, Gene Expression Regulation, Neoplastic, Cell Line, Tumor, Immune Evasion, B7-H1 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.